Grifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA margin 15.9%.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA margin 15.9%.
Trade closed: stop reached:
Mar 23